<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80711">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02041247</url>
  </required_header>
  <id_info>
    <org_study_id>IPROTECT1</org_study_id>
    <secondary_id>2013-002735-23</secondary_id>
    <nct_id>NCT02041247</nct_id>
  </id_info>
  <brief_title>Assessment of the Therapeutic Properties of the VAC-3S Immunoprotective Vaccine When Combined With Standard ART in the Course of HIV-1 Infection</brief_title>
  <official_title>Assessment of the Therapeutic Properties of the VAC-3S Immunoprotective Vaccine When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnaVirVax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnaVirVax</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV
      patients receiving standard of care antiretroviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>anti-3S antibodies titer</measure>
    <time_frame>From D0 to week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>tolerance to 6 vaccinations of VAC-3S</measure>
    <time_frame>From D0 to week 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) adverse events (AEs) grading table.Safety parameters include adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, viral load, CD4 and CD8 counts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood inflammatory marker concentrations</measure>
    <time_frame>From D0 to week 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inflammatory markers include: Highly sensitive C-reactive protein (hsCRP), Highly sensitive Recombinant human interleukin 6 (hsIL-6), Soluble CD14 (sCD14), Soluble CD163 (sCD163), D-dimer, Interferon (IFN)-gamma inducible protein 10 (IP-10), Tumor necrosis factor receptor 1 (sTNFR1) and 2 (sTNFR2), Immunoglobulin G (IgG),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenic characteristics of VAC-3S</measure>
    <time_frame>From D0 to week 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>anti-3S antibody titers and determination of anti-3S antibody isotypes and avidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte phenotype markers</measure>
    <time_frame>From D0 to week 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phenotype markers include: Nkp44L expression on the surface of CD4+ T lymphocytes, phenotypic markers of of lymphocyte differentiation and activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary virological effects</measure>
    <time_frame>From D0 to week 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>3S gp41 sequences and  proviral HIV reservoir</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>VAC-3S 16µg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC-3S Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC-3S 32 µg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC-3S 64 µg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAC-3S</intervention_name>
    <arm_group_label>VAC-3S 16µg/ml</arm_group_label>
    <arm_group_label>VAC-3S Placebo</arm_group_label>
    <arm_group_label>VAC-3S 32 µg/ml</arm_group_label>
    <arm_group_label>VAC-3S 64 µg/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented HIV-1 infection,

          2. Adults &gt; 18 and &lt; 60 years of age,

          3. Able and willing to comply with the protocol, including availability for all
             scheduled study visits,

          4. Provided a signed written informed consent,

          5. Meets study screening physical, medical history and laboratory assessments (defined
             below),

          6. On stable antiretroviral therapy that is consistent with the current standard of care
             for at least 12 months prior to study screening,

          7. Plasma HIV RNA &lt; 50 cps/mL during the previous 12 months,

          8. CD4+ T cell count at screening &gt; 200 and &lt; 500 cells/mm3,

          9. Adequate hematology, biochemistry, and metabolic blood tests defined as being less
             than grade 2 according to the Division of AIDS Adverse Events (See Appendix 23.1),
             except for the numeration of CD4 and for the numeration of lymphocytes,

         10. Adequate hepatic and renal function defined as being less than Grade 2 according to
             the Division of AIDS Adverse Events (See Appendix 23.1),

         11. Female patients of childbearing age with one documented negative blood pregnancy
             tests between Screening and Visit 1/Month 0; Female patient of childbearing potential
             must be receiving two forms of effective contraception and must be willing to use
             them throughout the study duration. These include oral, transdermal, systemic or
             implant contraception birth control, intra-uterine devices (IUD), abstinence and
             double barrier method such as diaphragm with spermicidal gel or other recommended
             double barrier method,

         12. Affiliated with the National Medical Insurance System,

         13. Believed by investigator to be able and willing to comply with the requirements of
             the study protocol and will be available for all scheduled visits at the study site.

        Exclusion Criteria:

          1. Not meeting all of the inclusion criteria listed above,

          2. Administration of any investigational drug or device within 28 days prior to
             screening,

          3. Prior history of an AIDS-defining event,

          4. Active co-infection with either HCV or HBV or any other active viral hepatitis
             co-infection,

          5. Any acute or clinically significant infections within the past month,

          6. Known allergy or intolerance to components of VAC-3S as documented through medical
             records or via patient interview,

          7. Chronic active liver disease as documented by any of the following laboratory
             assessments: ultrasound, clinical assessment, liver biopsy or equivalent non-invasive
             methods,

          8. Receipt of any known vaccinations within the past 1 month prior to screening,

          9. Receipt of any agent in the past 12 months that exerts a known immunological effect
             (e.g. includes but not limited to IL-2, IL-7, growth hormone…),

         10. Patients with Insulin Dependent Diabetes Mellitus, patients receiving anti-diabetic
             treatment, anticoagulants (excluding daily &quot;baby-dose&quot; aspirin) or daily NSAIDs
             within one week of study enrollment,

         11. Receipt of any contraindicated medications listed in Appendix 23.2,

         12. History of or active auto-immune disease,

         13. Acute or chronic psychiatric conditions which in the opinion of the investigator
             would need continual psychological support and/or medications incompatible with study
             participation,

         14. Patients with contraindications to intramuscular injections including, but not
             limited to, patients with thrombocytopenia and/or anomalies of the coagulation
             system,

         15. Any uncontrolled chronic or acute condition that in the opinion of the investigator
             would compromise safety of the patient or the ability to properly administer the
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>raphael ho tsong fang, DVM PhD</last_name>
    <role>Study Director</role>
    <affiliation>InnaVirVax</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphaël Ho Tsong Fang, DVM, PhD</last_name>
    <phone>+33 1 60 87 89 40</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Cotte, Dr</last_name>
      <phone>+33 (0)4 72 07 18 99</phone>
    </contact>
    <investigator>
      <last_name>Laurent Cotte, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Reynes, Pr</last_name>
      <phone>+33 (0)4 67 33 72 14</phone>
    </contact>
    <investigator>
      <last_name>Jacques Reynes, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Katlama, MD, PhD</last_name>
      <phone>+33 1 42 16 01 42</phone>
    </contact>
    <investigator>
      <last_name>Christine Katalama, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie Girard, Pr</last_name>
      <phone>+33 (0)1 49 28 24 38</phone>
    </contact>
    <investigator>
      <last_name>Pierre-Marie Girard, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile Launay, Pr</last_name>
      <phone>+33 (0)1 58 41 28 58</phone>
    </contact>
    <investigator>
      <last_name>Odile Launay, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Pialoux, Pr</last_name>
      <phone>+33 (0)1 56 01 74 12</phone>
    </contact>
    <investigator>
      <last_name>GIlles Pialoux, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Simon, Dr</last_name>
      <phone>+33 (0)1 42 16 10 93</phone>
    </contact>
    <investigator>
      <last_name>Anne Simon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jürgen Rockstroh</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Rockstroh, Pr</last_name>
      <phone>+49 (0)228 287 16558</phone>
    </contact>
    <investigator>
      <last_name>Jürgen Rockstroh, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Gatell, Pr</last_name>
      <phone>+34 (0)93 227 54 30</phone>
    </contact>
    <investigator>
      <last_name>Jose Gatell, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
